Literature DB >> 25814364

Glucagon--Early breakthroughs and recent discoveries.

Bo Ahrén1.   

Abstract

Glucagon was discovered in 1922 as a hyperglycemic factor in the pancreas. During its early history up to 1970, glucagon was shown to increase circulating glucose through stimulating glycogenolysis in the liver. It was also shown to be a constituent of islet non-β cells and to signal through G protein coupled receptors and cyclic AMP. Furthermore, its chemical characteristics, including amino acid sequence, and its processing from the preproglucagon gene had been established. During the modern research during the last 40 years, glucagon has been established as a key hormone in the regulation of glucose homeostasis, including a key role for the glucose counterregulation to hypoglycemia and for development of type 2 diabetes, and today glucagon is a potential target for treatment of the disease. Glucagon has also been shown to be a key factor beyond glucose control and involved in many processes. For the coming, future research, studies will be focused on α-cell biology beyond glucagon, hyperglucagonemia in other conditions than diabetes, its involvement in the regulation of body weight and energy expenditure and the potential of glucagon as a target for other diseases than type 2 diabetes, such as type 1 diabetes and obesity. This review summarizes the more than 90 years history of this important hormone as well as discusses potential future research regarding glucagon.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Diabetes; Glucagon; Glucose; History

Mesh:

Substances:

Year:  2015        PMID: 25814364     DOI: 10.1016/j.peptides.2015.03.011

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  29 in total

1.  An overview of glucagon research.

Authors:  Isabel Valverde
Journal:  Diabetologia       Date:  2016-04-26       Impact factor: 10.122

2.  Glucagon increases insulin levels by stimulating insulin secretion without effect on insulin clearance in mice.

Authors:  Gina Song; Giovanni Pacini; Bo Ahrén; David Z D'Argenio
Journal:  Peptides       Date:  2016-12-21       Impact factor: 3.750

Review 3.  Evolving function and potential of pancreatic alpha cells.

Authors:  Violeta Stanojevic; Joel F Habener
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2015-10-08       Impact factor: 4.690

Review 4.  Improved glucose regulation in type 2 diabetic patients with DPP-4 inhibitors: focus on alpha and beta cell function and lipid metabolism.

Authors:  Bo Ahrén; James E Foley
Journal:  Diabetologia       Date:  2016-02-19       Impact factor: 10.122

5.  Intra-islet glucagon signaling is critical for maintaining glucose homeostasis.

Authors:  Lu Zhu; Diptadip Dattaroy; Jonathan Pham; Lingdi Wang; Luiz F Barella; Yinghong Cui; Kenneth J Wilkins; Bryan L Roth; Ute Hochgeschwender; Franz M Matschinsky; Klaus H Kaestner; Nicolai M Doliba; Jürgen Wess
Journal:  JCI Insight       Date:  2019-04-23

Review 6.  Glucosensing in the gastrointestinal tract: Impact on glucose metabolism.

Authors:  Audren Fournel; Alysson Marlin; Anne Abot; Charles Pasquio; Carla Cirillo; Patrice D Cani; Claude Knauf
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-03-03       Impact factor: 4.052

Review 7.  The Three Ds of Transcription Activation by Glucagon: Direct, Delayed, and Dynamic.

Authors:  Ido Goldstein; Gordon L Hager
Journal:  Endocrinology       Date:  2018-01-01       Impact factor: 4.736

8.  A Light Activated Glucagon Trimer with Resistance to Fibrillation.

Authors:  Swetha Chintala; Simon H Friedman
Journal:  ACS Biomater Sci Eng       Date:  2021-03-11

Review 9.  In Vivo Metabolic Roles of G Proteins of the Gi Family Studied With Novel Mouse Models.

Authors:  Jürgen Wess
Journal:  Endocrinology       Date:  2022-01-01       Impact factor: 4.736

Review 10.  Glucose-lowering action through targeting islet dysfunction in type 2 diabetes: Focus on dipeptidyl peptidase-4 inhibition.

Authors:  Bo Ahrén
Journal:  J Diabetes Investig       Date:  2021-05-24       Impact factor: 4.232

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.